In today’s recent session, 11.2 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.85. Most recently the company’s share price was $7.78, and it changed around $0.29 or 3.94% from the last close, which brings the market valuation of the company to $3.04B. RXRX at last check was trading at a discount to its 52-week high of $15.74, offering almost -102.31% off that amount. The share price’s 52-week low was $5.60, which indicates that the recent value has risen by an impressive 28.02% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 22.42 million shares, with the 3-month average coming to 16.47 million.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.43. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Recursion Pharmaceuticals Inc is expected to report earnings per share of -0.42 for the current quarter.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing a green trend so far today with a performance of 3.94% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 8.28 on recent trading dayincreased the stock’s daily price by 6.04%. The company’s shares are currently up 15.16% year-to-date, but still up 7.38% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 7.23% up in the 30-day period. We can see from the shorts that 67.86 million shares have been sold at a short interest cover period of 4.15 day(s).
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 29.27% from its current value. Analyst projections state that RXRX is forecast to be at a low of $6 and a high of $12.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The year-over-year growth rate is expected to be 52.11%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 19.04M in revenue for the current quarter. 3 analysts expect Recursion Pharmaceuticals Inc to make 12M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.89M and 13.79M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 74.85%. Forecasts for the next quarter put sales growth at -13.01%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by 2.61% in 2025, but the outlook is positive 4.49% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in March.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.72% of Recursion Pharmaceuticals Inc shares, and 69.63% of them are in the hands of institutional investors. The stock currently has a share float of 72.32%. Recursion Pharmaceuticals Inc stock is held by 372.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 11.924% of the shares, which is about 28.14 million shares worth $211.07 million.
BAILLIE GIFFORD & CO, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 18.28 shares worth $143.02 million, making up 4.76% of all outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held roughly 11.51 shares worth around $90.04 million, which represents about 3.00% of the total shares outstanding.
